Sox9 transcriptionally represses spp1 to prevent matrix mineralization in maturing heart valves and chondrocytes

PLoS ONE

Volumn 6, Issue 10, 2011, Pages

  Peacock, Jacqueline D ^a   Huk, Danielle J ^a,b   Ediriweera, Hasini N ^a   Lincoln, Joy ^a,b  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

OSTEOPONTIN; TRANSCRIPTION FACTOR SOX9; REPRESSOR PROTEIN; SOX9 PROTEIN, MOUSE; SPP1 PROTEIN, MOUSE;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CARTILAGE CELL; CARTILAGE LINK PROTEIN GENE; CONTROLLED STUDY; EXPLANT; GENE; GENE EXPRESSION; GENE REPRESSION; GENE SILENCING; HEART VALVE; HUMAN; HUMAN CELL; MATRIX MINERALIZATION; MATURATION; MINERALIZATION; MOUSE; NEWBORN; NONHUMAN; NUCLEOTIDE SEQUENCE; PERINATAL PERIOD; PROTEIN BINDING; PROTEIN FUNCTION; RIB CARTILAGE; SPP1 GENE; TRANSACTIVATION; TYPE II COLLAGEN GENE; ANIMAL; CALCINOSIS; CHONDROGENESIS; DRUG ANTAGONISM; EXTRACELLULAR MATRIX; GENETIC TRANSCRIPTION; GENETICS; METABOLISM; PATHOLOGY; PHYSIOLOGY;

ANIMALS; CALCINOSIS; CHONDROCYTES; CHONDROGENESIS; EXTRACELLULAR MATRIX; HEART VALVES; MICE; OSTEOPONTIN; REPRESSOR PROTEINS; SOX9 TRANSCRIPTION FACTOR; TRANSCRIPTION, GENETIC;

EID: 80055026826     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0026769     Document Type: Article

References (50)

1. Lefebvre V, Smits P, (2005) Transcriptional control of chondrocyte fate and differentiation. Birth Defects Res C Embryo Today 75: 200-212.
2. Provot S, Schipani E, (2005) Molecular mechanisms of endochondral bone development. Biochem Biophys Res Commun 328: 658-665.
3. Mackie EJ, Ahmed YA, Tatarczuch L, Chen KS, Mirams M, (2008) Endochondral ossification: how cartilage is converted into bone in the developing skeleton. Int J Biochem Cell Biol 40: 46-62.
4. Akiyama H, (2008) Control of chondrogenesis by the transcription factor Sox9. Mod Rheumatol 18: 213-219.
5. Jenkins E, Moss JB, Pace JM, Bridgewater LC, (2005) The new collagen gene COL27A1 contains SOX9-responsive enhancer elements. Matrix Biol 24: 177-184.
6. Genzer MA, Bridgewater LC, (2007) A Col9a1 enhancer element activated by two interdependent SOX9 dimers. Nucleic Acids Res 35: 1178-1186.
7. Bridgewater LC, Lefebvre V, de Crombrugghe B, (1998) Chondrocyte-specific enhancer elements in the Col11a2 gene resemble the Col2a1 tissue-specific enhancer. J Biol Chem 273: 14998-15006.
8. Kou I, Ikegawa S, (2004) SOX9-dependent and-independent transcriptional regulation of human cartilage link protein. J Biol Chem 279: 50942-50948.
9. Sekiya I, Tsuji K, Koopman P, Watanabe H, Yamada Y, et al. (2000) SOX9 enhances aggrecan gene promoter/enhancer activity and is up-regulated by retinoic acid in a cartilage-derived cell line, TC6. J Biol Chem 275: 10738-10744.
10. Ng LJ, Wheatley S, Muscat GE, Conway-Campbell J, Bowles JE, et al. (1997) SOX9 binds DNA, activates transcription, and coexpresses with type II collagen during chondrogenesis in the mouse. Dev Biol 183.
11. Akiyama H, Chaboissier MC, Martin JF, Schedl A, de Crombrugghe B, (2002) The transcription factor Sox9 has essential roles in successive steps of the chondrocyte differentiation pathway and is required for expression of Sox5 and Sox6. Genes Dev 16: 2813-2828.
12. Bi W, Deng JM, Zhang Z, Behringer RR, de Crombrugghe B, (1999) Sox9 is required for cartilage formation. Nat Genet 22: 85-89.
13. Bi W, Huang W, Whitworth DJ, Deng JM, Zhang Z, et al. (2001) Haploinsufficiency of Sox9 results in defective cartilage primordia and premature skeletal mineralization. Proc Natl Acad Sci U S A 98: 6698-6703.
14. Foster JW, Dominguez-Steglich MA, Guioli S, Kwok C, Weller PA, et al. (1994) Campomelic dysplasia and autosomal sex reversal caused by mutations in an SRY-related gene. Nature 372: 525-530.
15. Wagner T, Wirth J, Meyer J, Zabel B, Held M, et al. (1994) Autosomal sex reversal and campomelic dysplasia are caused by mutations in and around the SRY-related gene SOX9. Cell 79: 1111-1120.
16. Hattori T, Muller C, Gebhard S, Bauer E, Pausch F, et al. (2010) SOX9 is a major negative regulator of cartilage vascularization, bone marrow formation and endochondral ossification. Development 137: 901-911.
17. Komori T, (2010) Regulation of bone development and extracellular matrix protein genes by RUNX2. Cell Tissue Res 339: 189-195.
18. Komori T, Yagi H, Nomura S, Yamaguchi A, Sasaki K, et al. (1997) Targeted disruption of Cbfa1 results in a complete lack of bone formation owing to maturational arrest of osteoblasts. Cell 89: 755-764.
19. Inada M, Yasui T, Nomura S, Miyake S, Deguchi K, et al. (1999) Maturational disturbance of chondrocytes in Cbfa1-deficient mice. Dev Dyn 214: 279-290.
20. Zhou G, Zheng Q, Engin F, Munivez E, Chen Y, et al. (2006) Dominance of SOX9 function over RUNX2 during skeletogenesis. Proc Natl Acad Sci U S A 103: 19004-19009.
21. Lincoln J, Kist R, Scherer G, Yutzey KE, (2007) Sox9 is required for precursor cell expansion and extracellular matrix organization during mouse heart valve development. Dev Biol 305: 120-132.
22. Akiyama H, Chaboissier MC, Behringer RR, Rowitch DH, Schedl A, et al. (2004) Essential role of Sox9 in the pathway that controls formation of cardiac valves and septa. Proc Natl Acad Sci U S A 101: 6502-6507.
23. Lincoln J, Lange AW, Yutzey KE, (2006) Hearts and bones: shared regulatory mechanisms in heart valve, cartilage, tendon, and bone development. Dev Biol 294: 292-302.
24. Lincoln J, Alfieri CM, Yutzey KE, (2004) Development of heart valve leaflets and supporting apparatus in chicken and mouse embryos. Dev Dyn 230: 239-250.
25. Peacock JD, Levay AK, Gillaspie DB, Tao G, Lincoln J, (2010) Reduced sox9 function promotes heart valve calcification phenotypes in vivo. Circ Res 106: 712-719.
26. Rajamannan NM, Subramaniam M, Rickard D, Stock SR, Donovan J, et al. (2003) Human aortic valve calcification is associated with an osteoblast phenotype. Circulation 107: 2181-2184.
27. Gordon JA, Tye CE, Sampaio AV, Underhill TM, Hunter GK, et al. (2007) Bone sialoprotein expression enhances osteoblast differentiation and matrix mineralization in vitro. Bone 41: 462-473.
28. Kojima H, Uede T, Uemura T, (2004) In vitro and in vivo effects of the overexpression of osteopontin on osteoblast differentiation using a recombinant adenoviral vector. Journal of Biochemistry 136: 377-386.
29. Shen Q, Christakos S, (2005) The vitamin D receptor, Runx2, and the Notch signaling pathway cooperate in the transcriptional regulation of osteopontin. J Biol Chem 280: 40589-40598.
30. Inman CK, Shore P, (2003) The osteoblast transcription factor Runx2 is expressed in mammary epithelial cells and mediates osteopontin expression. J Biol Chem 278: 48684-48689.
31. Mertin S, McDowall SG, Harley VR, (1999) The DNA-binding specificity of SOX9 and other SOX proteins. Nucleic acids research 27: 1359-1364.
32. Shibata S, Fukada K, Suzuki S, Ogawa T, Yamashita Y, (2002) In situ hybridization and immunohistochemistry of bone sialoprotein and secreted phosphoprotein 1 (osteopontin) in the developing mouse mandibular condylar cartilage compared with limb bud cartilage. Journal of Anatomy 200: 309-320.
33. Alexopoulos A, Bravou V, Peroukides S, Kaklamanis L, Varakis J, et al. (2010) Bone regulatory factors NFATc1 and Osterix in human calcific aortic valves. International journal of cardiology 139: 142-149.
34. Caira FC, Stock SR, Gleason TG, McGee EC, Huang J, et al. (2006) Human degenerative valve disease is associated with up-regulation of low-density lipoprotein receptor-related protein 5 receptor-mediated bone formation. Journal of the American College of Cardiology 47: 1707-1712.
35. Lehmann S, Walther T, Kempfert J, Rastan A, Garbade J, et al. (2009) Mechanical strain and the aortic valve: influence on fibroblasts, extracellular matrix, and potential stenosis. The Annals of thoracic surgery 88: 1476-1483.
36. Mohler ER III, Adam LP, McClelland P, Graham L, Hathaway DR, (1997) Detection of osteopontin in calcified human aortic valves. Arteriosclerosis, thrombosis, and vascular biology 17: 547-552.
37. O'Brien KD, Kuusisto J, Reichenbach DD, Ferguson M, Giachelli C, et al. (1995) Osteopontin is expressed in human aortic valvular lesions. Circulation 92: 2163-2168.
38. Rennenberg RJ, Schurgers LJ, Kroon AA, Stehouwer CD, (2010) Arterial calcifications. Journal of cellular and molecular medicine 14: 2203-2210.
39. Oldberg A, Franzen A, Heinegard D, (1986) Cloning and sequence analysis of rat bone sialoprotein (osteopontin) cDNA reveals an Arg-Gly-Asp cell-binding sequence. Proceedings of the National Academy of Sciences of the United States of America 83: 8819-8823.
40. Anderson HC, (1983) Calcific diseases. A concept. Archives of pathology & laboratory medicine 107: 341-348.
41. Thurner PJ, Chen CG, Ionova-Martin S, Sun L, Harman A, et al. (2010) Osteopontin deficiency increases bone fragility but preserves bone mass. Bone 46: 1564-1573.
42. Speer MY, McKee MD, Guldberg RE, Liaw L, Yang HY, et al. (2002) Inactivation of the osteopontin gene enhances vascular calcification of matrix Gla protein-deficient mice: evidence for osteopontin as an inducible inhibitor of vascular calcification in vivo. The Journal of experimental medicine 196: 1047-1055.
43. Ohri R, Tung E, Rajachar R, Giachelli CM, (2005) Mitigation of ectopic calcification in osteopontin-deficient mice by exogenous osteopontin. Calcified tissue international 76: 307-315.
44. Hinton RB Jr, Lincoln J, Deutsch GH, Osinska H, Manning PB, et al. (2006) Extracellular matrix remodeling and organization in developing and diseased aortic valves. Circulation research 98: 1431-1438.
45. Kawakami Y, Tsuda M, Takahashi S, Taniguchi N, Esteban CR, et al. (2005) Transcriptional coactivator PGC-1alpha regulates chondrogenesis via association with Sox9. Proceedings of the National Academy of Sciences of the United States of America 102: 2414-2419.
46. Furumatsu T, Tsuda M, Taniguchi N, Tajima Y, Asahara H, (2005) Smad3 induces chondrogenesis through the activation of SOX9 via CREB-binding protein/p300 recruitment. J Biol Chem 280: 8343-8350.
47. Cheng CC, Uchiyama Y, Hiyama A, Gajghate S, Shapiro IM, et al. (2009) PI3K/AKT regulates aggrecan gene expression by modulating Sox9 expression and activity in nucleus pulposus cells of the intervertebral disc. Journal of cellular physiology 221: 668-676.
48. Pan Q, Wu Y, Lin T, Yao H, Yang Z, et al. (2009) Bone morphogenetic protein-2 induces chromatin remodeling and modification at the proximal promoter of Sox9 gene. Biochemical and biophysical research communications 379: 356-361.
49. Grogan SP, Olee T, Hiraoka K, Lotz MK, (2008) Repression of chondrogenesis through binding of notch signaling proteins HES-1 and HEY-1 to N-box domains in the COL2A1 enhancer site. Arthritis and rheumatism 58: 2754-2763.
50. Thirion S, Berenbaum F, (2004) Culture and phenotyping of chondrocytes in primary culture. Methods Mol Med 100: 1-14.